NNZ-2566 + Placebo

Phase 1Completed

0 views this week 0 watching💤 Quiet

Interest: 23/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Brain Injuries, Traumatic

Conditions

Brain Injuries, Traumatic

Trial Timeline

Feb 1, 2012 → Sep 1, 2012

NCT ID

NCT01420042

About NNZ-2566 + Placebo

NNZ-2566 + Placebo is a phase 1 stage product being developed by Neuren Pharmaceuticals for Brain Injuries, Traumatic. The current trial status is completed. This product is registered under clinical trial identifier NCT01420042. Target conditions include Brain Injuries, Traumatic.

What happened to similar drugs?

5 of 18 similar drugs in Brain Injuries, Traumatic were approved

Approved (5) Terminated (2) Active (13)

🔄Nivolumab + TemozolomideOno PharmaceuticalPhase 3

✅ExenatideAstraZenecaApproved

🔄temozolomideMerckPhase 3

🔄RivastigmineNovartisPhase 3

✅RivastigmineNovartisApproved

🔄capecitabine + lapatinib + trastuzumabNovartisPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (8)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02715115	Phase 2	Completed	Mar 1, 2016	Jan 5, 2017	Rett Syndrome
NCT02100150	Phase 2	Terminated	Sep 1, 2014	Jun 1, 2016	Concussion
NCT01894958	Phase 2	Completed	Jan 1, 2014	Oct 1, 2015	Fragile X Syndrome
NCT01703533	Phase 2	Completed	Mar 1, 2013	Sep 1, 2014	Rett Syndrome
NCT01366820	Phase 2	Completed	Feb 1, 2013	Jan 1, 2016	Brain Injuries
NCT01420042	Phase 1	Completed	Feb 1, 2012	Sep 1, 2012	Brain Injuries, Traumatic
NCT00805818	Phase 2	Completed	Apr 1, 2010	Jan 1, 2016	Brain Injuries
NCT00961779	Phase 1	Completed	Mar 1, 2010	Sep 1, 2010	Brain Injuries, Traumatic

Competing Products

20 competing products in Brain Injuries, Traumatic

See all competitors

Product	Company	Stage	Hype Score
Abemaciclib + Endocrine therapy	Eli Lilly	Phase 1/2	39
Duloxetine + Sugar pill	Eli Lilly	Phase 2	27
Neurosteroid enantiomer	Oragenics	Phase 2	32
Patritumab deruxtecan	Daiichi Sankyo	Phase 2	27
filgrastim + exatecan mesylate	Daiichi Sankyo	Phase 1	29
Eribulin Mesylate	Eisai	Phase 1	29
Pembrolizumab + Lenvatinib	Eisai	Phase 2	42
Palonosetron (Aloxi) and Dexamethasone	Eisai	Phase 2	27
GLIADEL	Eisai	Phase 2	35
Nivolumab + Temozolomide	Ono Pharmaceutical	Phase 3	40
Nivolumab + Temozolomide	Ono Pharmaceutical	Phase 3	40
Prexasertib + Cyclophosphamide + Gemcitabine + filgrastim + peg-filgrastim	Eli Lilly	Phase 1	29
abemaciclib + abemaciclib	Eli Lilly	Phase 2	39
JNJ-17299425	Johnson & Johnson	Phase 2	27
ABT-888	AbbVie	Phase 1	29
Veliparib + Placebo	AbbVie	Phase 2	35
Iressa (Gefitinib)	AstraZeneca	Phase 2	27
Trastuzumab deruxtecan	AstraZeneca	Phase 2	42
Exenatide	AstraZeneca	Approved	43
AZD5213	AstraZeneca	Phase 1	29